Patient-reported outcomes in european spondyloarthritis patients: a systematic review of the literature

Objective: This review aims to summarize the current literature on patient-reported outcomes (PROs) in spondyloarthritis (SpA). Patients and methods: We performed a systematic literature review to identify studies (origi-nal articles and narrative and systematic reviews) regarding PROs (health-related quality of life [HRQoL], satisfaction, preferences, adherence/compliance, and persistence) in SpA patients published in the European Union through December 2016. International databases (Medline/ PubMed, Cochrane Library, ISI Web of Knowledge, Scopus) were searched using keywords in English. The methodological quality of the studies was assessed using the Oxford Centre for Evidence-Based Medicine criteria. Results: A total of 26 publications met the inclusion criteria. Generally, studies indicated that SpA has a negative impact on patients’ HRQoL. In patients with ankylosing spondylitis, physical domains were more affected than emotional ones, whereas for psoriatic arthritis, both physical and psychological factors were strongly affected by the disease. Data indicated that biological agents (BAs) greatly contributed to improvement in HRQoL in both ankylosing spondylitis and psoriatic arthritis patients. Findings on compliance with BAs were heterogeneous. However, persistence rates exceeded 50% irrespective of the BA administered. Results on preferences indicated that most SpA patients prefer being involved in decisions regarding their treatment and that besides efficacy and safety, frequency and route of administration may influence patients’ preferences for BAs. Conclusion: Implementing management programs for SpA patients focuses on the physical, emotional, and social consequences of the disease, in addition to assessing and including patient preferences in the treatment decision-making process, could be crucial to improve patients’ HRQoL and ensure their satisfaction and compliance with treatment. relapse in exchange for improvements in levels of sickness/nausea (76.1% severe to some sickness/nausea, 32.6% some to no sickness/ nausea) and health status (30.1% health state 3 [no problems with mobility or self-care, some problems with performing usual activities, moderate pain or discomfort, and moderate anxiety or depression] to 2 [no problems with mobility, self-care, anxiety, or depression, some problems with performing usual activities, moderate pain or discomfort], 38.6% health state 1 [no problems with mobility or self-care, usual activities, pain or discomfort, anxiety or depression] to 3).

[1]  R. Anguiano,et al.  Medication adherence and persistence over time with self-administered TNF-alpha inhibitors among young adult, middle-aged, and older patients with rheumatologic conditions. , 2017, Seminars in arthritis and rheumatism.

[2]  M. Dougados,et al.  Associations Between Five Important Domains of Health and the Patient Acceptable Symptom State in Rheumatoid Arthritis and Psoriatic Arthritis: A Cross‐Sectional Study of 977 Patients , 2017, Arthritis care & research.

[3]  C. Selmi,et al.  Eight‐Year Retention Rate of First‐Line Tumor Necrosis Factor Inhibitors in Spondyloarthritis: A Multicenter Retrospective Analysis , 2017, Arthritis care & research.

[4]  S. Raychaudhuri,et al.  Mechanistic rationales for targeting interleukin-17A in spondyloarthritis , 2017, Arthritis Research & Therapy.

[5]  L. Coates,et al.  A discrete choice experiment to explore patients’ willingness to risk disease relapse from treatment withdrawal in psoriatic arthritis , 2016, Clinical Rheumatology.

[6]  J. Sieper,et al.  Burden of illness associated with non-radiographic axial spondyloarthritis: a multiperspective European cross-sectional observational study. , 2016, Clinical and experimental rheumatology.

[7]  P. Kawalec,et al.  Disease activity, quality of life and indirect costs of psoriatic arthritis in Poland , 2016, Rheumatology International.

[8]  G. Nocea,et al.  Patients’ and rheumatologists’ preferences for the attributes of biological agents used in the treatment of rheumatic diseases in Spain , 2016, Patient preference and adherence.

[9]  F. Wilson,et al.  Decreased health-related physical fitness in adults with ankylosing spondylitis: a cross-sectional controlled study. , 2016, Physiotherapy.

[10]  M. D. de Wit,et al.  Patient global assessment in psoriatic arthritis - what does it mean? An analysis of 223 patients from the Psoriatic arthritis impact of disease (PsAID) study. , 2016, Joint, bone, spine : revue du rhumatisme.

[11]  P. Geborek,et al.  Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients – baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice , 2015, Arthritis Research & Therapy.

[12]  T. Soukup,et al.  Quality of life and drug compliance: their interrelationship in rheumatic patients. , 2015, Journal of evaluation in clinical practice.

[13]  M. Dougados,et al.  Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update , 2015, Annals of the rheumatic diseases.

[14]  D. Wendling.  Treating to target in axial spondyloarthritis: defining the target and the arrow , 2015, Expert review of clinical immunology.

[15]  M. Redondo,et al.  Adherence to biologic therapies and associated factors in rheumatoid arthritis, spondyloarthritis and psoriatic arthritis: a systematic literature review. , 2015, Clinical and experimental rheumatology.

[16]  L. March,et al.  The global challenges and opportunities in the practice of rheumatology: White paper by the World Forum on Rheumatic and Musculoskeletal Diseases , 2014, Clinical Rheumatology.

[17]  J. Poveda,et al.  Treatment adherence and other patient-reported outcomes as cost determinants in multiple sclerosis: a review of the literature , 2014, Patient preference and adherence.

[18]  C. Drossaert,et al.  Patient participation in decisions about disease modifying anti-rheumatic drugs: a cross-sectional survey , 2014, BMC Musculoskeletal Disorders.

[19]  Kow-Tong Chen,et al.  Psoriatic arthritis: Epidemiology, diagnosis, and treatment. , 2014, World journal of orthopedics.

[20]  Désirée van der Heijde,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update , 2013, Annals of the rheumatic diseases.

[21]  A. Carvalho,et al.  The relationship between depressive symptoms, illness perceptions and quality of life in ankylosing spondylitis in comparison to rheumatoid arthritis , 2013, Clinical Rheumatology.

[22]  A. Carvalho,et al.  Anxiety and depressive symptoms and illness perceptions in psoriatic arthritis and associations with physical health‐related quality of life , 2012, Arthritis care & research.

[23]  E. Kucharz,et al.  Opinion of patients with ankylosing spondylitis on risk factors impairing their quality of life , 2012, Rheumatology International.

[24]  Carmen Stolwijk,et al.  Epidemiology of spondyloarthritis. , 2012, Rheumatic diseases clinics of North America.

[25]  C. V. D. van den Ende,et al.  Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature , 2012, Expert review of clinical immunology.

[26]  C. Di Pietro,et al.  Participation, satisfaction and knowledge level of patients with cutaneous psoriasis or psoriatic arthritis , 2011, Clinical and experimental dermatology.

[27]  N. Vøllestad,et al.  Physical Fitness in Patients With Ankylosing Spondylitis: Comparison With Population Controls , 2011, Physical Therapy.

[28]  M. Dougados,et al.  European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies , 2011, Annals of the rheumatic diseases.

[29]  M. Dougados,et al.  2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis , 2011, Annals of the rheumatic diseases.

[30]  F. Inanici,et al.  Reduced vital capacity leads to exercise intolerance in patients with ankylosing spondylitis. , 2011, European journal of physical and rehabilitation medicine.

[31]  M. Englund,et al.  Presence of peripheral arthritis and male sex predicting continuation of anti–tumor necrosis factor therapy in ankylosing spondylitis: An observational prospective cohort study from the South Swedish arthritis treatment group register , 2010, Arthritis care & research.

[32]  P. Balint,et al.  Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire, the functional status (HAQ) and utility (EQ-5D) measures in psoriatic arthritis: results from a cross-sectional survey , 2010, Scandinavian journal of rheumatology.

[33]  John Wong,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs , 2010, Annals of the rheumatic diseases.

[34]  D. Symmons,et al.  Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti–tumor necrosis factor therapies , 2010, Arthritis care & research.

[35]  D. Globe,et al.  Trends in RA patients’ adherence to subcutaneous anti-TNF therapies and costs , 2009, Current medical research and opinion.

[36]  J. Singh,et al.  Spondyloarthritis Is Associated with Poor Function and Physical Health-Related Quality of Life , 2009, The Journal of Rheumatology.

[37]  D. Symmons,et al.  Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register , 2009, Arthritis research & therapy.

[38]  C. Chevat,et al.  Development and psychometric validation of a self-administered questionnaire assessing the acceptance of influenza vaccination: the Vaccinees' Perception of Injection (VAPI©) questionnaire , 2009, Health and quality of life outcomes.

[39]  L. Carmona,et al.  Multimorbidity: prevalence, effect on quality of life and daily functioning, and variation of this effect when one condition is a rheumatic disease. , 2009, Seminars in arthritis and rheumatism.

[40]  B. Hernández-Cruz,et al.  Variables related to utility in patients with ankylosing spondylitis , 2009, Clinical Rheumatology.

[41]  R. Campbell,et al.  Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter? , 2008, Arthritis and rheumatism.

[42]  A. Boonen,et al.  Identification of the most common problems by patients with ankylosing spondylitis using the international classification of functioning, disability and health. , 2006, The Journal of rheumatology.

[43]  Samuele M. Marcora,et al.  Preliminary evidence for cachexia in patients with well-established ankylosing spondylitis. , 2006, Rheumatology.

[44]  T. Pincus,et al.  Changes in Health Assessment Questionnaire disability scores over five years in patients with rheumatoid arthritis compared with the general population. , 2006, Arthritis and rheumatism.

[45]  Jackie Hill,et al.  Adherence with drug therapy in the rheumatic diseases Part one: a review of adherence rates. , 2005, Musculoskeletal care.

[46]  D. Gladman,et al.  Psoriatic arthritis: epidemiology, clinical features, course, and outcome , 2005, Annals of the rheumatic diseases.

[47]  Stanley B. Cohen,et al.  The evolving use of tumor necrosis factor inhibitors in rheumatoid arthritis. , 2004, The Journal of rheumatology.

[48]  S. van der Linden,et al.  Quality of life and work in patients with rheumatoid arthritis and ankylosing spondylitis of working age , 2003, Annals of the rheumatic diseases.

[49]  J. Frytak,et al.  Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. , 2003, The American journal of managed care.

[50]  B. Hernández-Cruz,et al.  Physical function and health-related quality of life of Spanish patients with ankylosing spondylitis. , 2003, Arthritis and rheumatism.

[51]  R. Kravitz,et al.  Engaging patients in medical decision making , 2001, BMJ : British Medical Journal.

[52]  D. Wendling,et al.  Bone density, ultrasound measurements and body composition in early ankylosing spondylitis. , 2001, Rheumatology.

[53]  R. Sturrock,et al.  An investigation of factors limiting aerobic capacity in patients with ankylosing spondylitis. , 1999, Respiratory medicine.

[54]  T. Fan,et al.  Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany , 2015, Rheumatology International.

[55]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration , 2013 .

[56]  I. Lukić,et al.  Which clinical variables have the most significant correlation with quality of life evaluated by SF-36 survey in Croatian cohort of patient with ankylosing spondylitis and psoriatic arthritis? , 2011, Rheumatology International.

[57]  A. El Maghraoui.  Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications. , 2011, European journal of internal medicine.

[58]  Anuja Roy,et al.  Medication compliance and persistence: terminology and definitions. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[59]  D Prakash,et al.  International Journal of Nanomedicine Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article , 1998 .